Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
https://www.pharmalive.com/wp-content/uploads/2020/07/Evive-Biotech-Sees-Positive-Results-in-Phase-III-Trial-for-CIN-in-Breast-Cancer-Patients-BioSpace-7-8-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-07-08 18:28:462020-07-15 21:23:30Positive Results in Phase III Trial for CIN in Breast Cancer Patients